The disease

Acute Myeloid Leukemia (AML) remains the deadliest leukemia type

Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal blood cells (blasts). The blasts build up in the bone marrow and blood and interfere with normal blood cell production. AML is the deadliest type of leukemia. AML progresses rapidly, and is typically fatal within weeks or months if left untreated. In 2015, AML affected about one million people, and resulted in 147,000 deaths globally. It is estimated that in the U.S. alone, more than 20,000 people were diagnosed with AML in 2022 and more than 11,000 died from the disease. From the time of diagnosis, the five-year survival rate is only about 30%. The current standard treatment of AML was developed in the 1970s and the patients are in desperate need of better treatment options. Glykos Biomedical is developing its novel drug to improve the outcome of AML patients.